High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis

Kim,Kyungeun; Ihm,Hyojin; Ro,Jae Y.; Cho,Yong Mee

doi:10.3892/ol.2011.368

High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis

Authors:
- Kyungeun Kim
- Hyojin Ihm
- Jae Y. Ro
- Yong Mee Cho
View Affiliations

Affiliations: Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul 138-736, Republic of Korea
Published online on: August 2, 2011 https://doi.org/10.3892/ol.2011.368
Pages: 1095-1100

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cancer stem cell (CSC) model suggests that high levels of CSCs within a tumor are associated with poor prognosis. The aim of this study was to investigate the expression of the stem cell marker CD133 in clear cell renal cell carcinoma (ccRCC), and its prognostic significance. The expression of CD133 was examined in 140 cases of ccRCC using immunohistochemistry. Ki-67 and Oct-4 were double-immunostained with CD133 to evaluate the proliferative activity and the stemness of CD133-expressing cells, respectively. CD133 expression was observed in 45 cases (32.1%) and high levels of expression were found to be associated with a macro-/microcystic pattern, non-sarcomatoid changes and non-metastatic disease. The Ki-67 labeling index tended to be lower in CD133-expressing ccRCCs compared to non-expressing tumors. CD133-expressing tumor cells rarely expressed Oct-4. A high degree of CD133 expression was observed in ccRCC with more differentiated morphology and non-metastatic disease, suggesting that CD133 is a favorable prognostic marker. These results also indicate that CD133 as a single marker may not be sufficient for CSC identification in ccRCC and, therefore, more specific CSC markers should be developed.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
2	Wein AJ, Kavoussi LR, Novick AC, Partin AW and Peters CA: Campbell-Walsh Urology. 9th edition. Saunders Elsevier; Philadelphia: 2007
3	Levy DA, Slaton JW, Swanson DA and Dinney CP: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 159:1163–1167. 1998. View Article : Google Scholar : PubMed/NCBI
4	Eble JN, Epstein JI and Sesterhenn IA: World Health Organization classification of tumors. IARC Press; Lyon: 2004
5	Kim HL, Seligson D, Liu X, et al: Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 10:5464–5471. 2004. View Article : Google Scholar : PubMed/NCBI
6	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
7	Clarke MF, Dick JE, Dirks PB, et al: Cancer stem cells – perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
8	Burkert J, Wright NA and Alison MR: Stem cells and cancer: an intimate relationship. J Pathol. 209:287–297. 2006. View Article : Google Scholar : PubMed/NCBI
9	Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T: Opinion: migrating cancer stem cells – an integrated concept of malignant tumour progression. Nat Rev Cancer. 5:744–749. 2005.PubMed/NCBI
10	Miraglia S, Godfrey W, Yin AH, et al: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 90:5013–5021. 1997.PubMed/NCBI
11	Mizrak D, Brittan M and Alison MR: CD133: molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
12	Horst D, Kriegl L, Engel J, Kirchner T and Jung A: Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 27:844–850. 2009. View Article : Google Scholar : PubMed/NCBI
13	Wang Q, Chen ZG, Du CZ, Wang HW, Yan L and Gu J: Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology. 55:284–293. 2009.
14	Kojima M, Ishii G, Atsumi N, Fujii S, Saito N and Ochiai A: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
15	Bussolati B, Bruno S, Grange C, et al: Isolation of renal progenitor cells from adult human kidney. Am J Pathol. 166:545–555. 2005. View Article : Google Scholar : PubMed/NCBI
16	Florek M, Haase M, Marzesco AM, et al: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 319:15–26. 2005. View Article : Google Scholar : PubMed/NCBI
17	Cheville JC, Lohse CM, Zincke H, Weaver AL and Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 27:612–624. 2003. View Article : Google Scholar : PubMed/NCBI
18	Cheng L, Sung MT, Cossu-Rocca P, et al: OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol. 211:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
19	Jones TD, Ulbright TM, Eble JN and Cheng L: OCT4: a sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res. 10:8544–8547. 2004. View Article : Google Scholar : PubMed/NCBI
20	Lengner CJ, Welstead GG and Jaenisch R: The pluripotency regulator Oct4: a role in somatic stem cells? Cell Cycle. 7:725–728. 2008. View Article : Google Scholar : PubMed/NCBI
21	Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
22	Greene FL and Fleming ID: AJCC Cancer Staging Manual. 6th edition. Springer-Verlag; Chicago: 2002, View Article : Google Scholar
23	Kim K, Lee KM, Han DJ, Yu E and Cho YM: Adult stem cell-like tubular cells reside in the corticomedullary junction of the kidney. Int J Clin Exp Pathol. 1:232–241. 2008.PubMed/NCBI
24	Gupta PB, Chaffer CL and Weinberg RA: Cancer stem cells: mirage or reality? Nat Med. 15:1010–1012. 2009. View Article : Google Scholar : PubMed/NCBI
25	Tirino V, Camerlingo R, Franco R, et al: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg. 36:446–453. 2009. View Article : Google Scholar : PubMed/NCBI
26	Rutella S, Bonanno G, Procoli A, et al: Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res. 15:4299–4311. 2009. View Article : Google Scholar : PubMed/NCBI
27	Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
28	O’Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007.PubMed/NCBI
29	Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
30	Zeppernick F, Ahmadi R, Campos B, et al: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
31	Artells R, Moreno I, Diaz T, et al: Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer. 46:642–649. 2010. View Article : Google Scholar : PubMed/NCBI
32	Todaro M, Alea MP, Di Stefano AB, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 1:389–402. 2007. View Article : Google Scholar : PubMed/NCBI
33	Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
34	Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA and Rosen JM: WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA. 104:618–623. 2007. View Article : Google Scholar : PubMed/NCBI
35	Chiou SH, Kao CL, Chen YW, et al: Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS One. 3:e20902008. View Article : Google Scholar : PubMed/NCBI
36	Smith LM, Nesterova A, Ryan MC, et al: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 99:100–109. 2008. View Article : Google Scholar : PubMed/NCBI
37	Ferrandina G, Martinelli E, Petrillo M, et al: CD133 antigen expression in ovarian cancer. BMC Cancer. 9:2212009. View Article : Google Scholar : PubMed/NCBI
38	Piras F, Perra MT, Murtas D, et al: The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep. 23:17–24. 2010.PubMed/NCBI
39	Bruno S, Bussolati B, Grange C, et al: CD133⁺ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol. 169:2223–2235. 2006.
40	Corbeil D, Roper K, Hellwig A, et al: The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 275:5512–5520. 2000. View Article : Google Scholar : PubMed/NCBI
41	Fargeas CA, Joester A, Missol-Kolka E, Hellwig A, Huttner WB and Corbeil D: Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci. 117:4301–4311. 2004. View Article : Google Scholar : PubMed/NCBI
42	Giebel B, Corbeil D, Beckmann J, et al: Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood. 104:2332–2338. 2004. View Article : Google Scholar : PubMed/NCBI
43	Weigmann A, Corbeil D, Hellwig A and Huttner WB: Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA. 94:12425–12430. 1997. View Article : Google Scholar
44	Corbeil D, Roper K, Fargeas CA, Joester A and Huttner WB: Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic. 2:82–91. 2001. View Article : Google Scholar : PubMed/NCBI
45	Rousseau A, Ayoubi F, Deveaux C, et al: Impact of age and gender interaction on circulating endothelial progenitor cells in healthy subjects. Fertil Steril. 93:843–846. 2010. View Article : Google Scholar : PubMed/NCBI
46	Lemieux C, Cloutier I and Tanguay JF: Menstrual cycle influences endothelial progenitor cell regulation: a link to gender differences in vascular protection? Int J Cardiol. 136:200–210. 2009. View Article : Google Scholar : PubMed/NCBI